265 related articles for article (PubMed ID: 34491549)
1. Recombinant adenovirus expressing the fusion protein PD1PVR improves CD8
Zhang H; Zhang Y; Dong J; Zuo S; Meng G; Wu J; Wei J
Cell Oncol (Dordr); 2021 Dec; 44(6):1243-1255. PubMed ID: 34491549
[TBL] [Abstract][Full Text] [Related]
2. Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1/CD137L Subverts the Suppression of CD8
Zhang Y; Zhang H; Wei M; Mou T; Shi T; Ma Y; Cai X; Li Y; Dong J; Wei J
Mol Ther; 2019 Nov; 27(11):1906-1918. PubMed ID: 31466933
[TBL] [Abstract][Full Text] [Related]
3. CD8
Xu C; Lu X; Liu W; Chen A; Meng G; Zhang H; Li B; Zhang Y; Wu J; Wei J
J Transl Med; 2018 May; 16(1):132. PubMed ID: 29784005
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic measles virus enhances antitumour responses of adoptive CD8
Chen A; Zhang Y; Meng G; Jiang D; Zhang H; Zheng M; Xia M; Jiang A; Wu J; Beltinger C; Wei J
Sci Rep; 2017 Jul; 7(1):5170. PubMed ID: 28701757
[TBL] [Abstract][Full Text] [Related]
5. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
6. Recombinant oncolytic adenovirus expressing a soluble PVR elicits long-term antitumor immune surveillance.
Zhang H; Zhang Y; Dong J; Li B; Xu C; Wei M; Wu J; Wei J
Mol Ther Oncolytics; 2021 Mar; 20():12-22. PubMed ID: 33575467
[TBL] [Abstract][Full Text] [Related]
7. An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade.
Zuo S; Wei M; Xu T; Kong L; He B; Wang S; Wang S; Wu J; Dong J; Wei J
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34949694
[TBL] [Abstract][Full Text] [Related]
8. Transcriptome Profiling Identifies TIGIT as a Marker of T-Cell Exhaustion in Liver Cancer.
Ostroumov D; Duong S; Wingerath J; Woller N; Manns MP; Timrott K; Kleine M; Ramackers W; Roessler S; Nahnsen S; Czemmel S; Dittrich-Breiholz O; Eggert T; Kühnel F; Wirth TC
Hepatology; 2021 Apr; 73(4):1399-1418. PubMed ID: 32716559
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
[TBL] [Abstract][Full Text] [Related]
10. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
[TBL] [Abstract][Full Text] [Related]
11. Targeting aerobic glycolysis by dichloroacetate improves Newcastle disease virus-mediated viro-immunotherapy in hepatocellular carcinoma.
Meng G; Li B; Chen A; Zheng M; Xu T; Zhang H; Dong J; Wu J; Yu D; Wei J
Br J Cancer; 2020 Jan; 122(1):111-120. PubMed ID: 31819179
[TBL] [Abstract][Full Text] [Related]
12. 4-1BB Delineates Distinct Activation Status of Exhausted Tumor-Infiltrating CD8
Kim HD; Park S; Jeong S; Lee YJ; Lee H; Kim CG; Kim KH; Hong SM; Lee JY; Kim S; Kim HK; Min BS; Chang JH; Ju YS; Shin EC; Song GW; Hwang S; Park SH
Hepatology; 2020 Mar; 71(3):955-971. PubMed ID: 31353502
[TBL] [Abstract][Full Text] [Related]
13. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
14. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
[TBL] [Abstract][Full Text] [Related]
15. PD-1
Liu X; Li M; Wang X; Dang Z; Jiang Y; Wang X; Kong Y; Yang Z
Cancer Immunol Immunother; 2019 Dec; 68(12):2041-2054. PubMed ID: 31720814
[TBL] [Abstract][Full Text] [Related]
16. Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model.
Li G; Liu D; Cooper TK; Kimchi ET; Qi X; Avella DM; Li N; Yang QX; Kester M; Rountree CB; Kaifi JT; Cole DJ; Rockey DC; Schell TD; Staveley-O'Carroll KF
J Hepatol; 2017 Jan; 66(1):75-85. PubMed ID: 27520877
[TBL] [Abstract][Full Text] [Related]
17. Characterizing responsive and refractory orthotopic mouse models of hepatocellular carcinoma in cancer immunotherapy.
Hage C; Hoves S; Ashoff M; Schandl V; Hört S; Rieder N; Heichinger C; Berrera M; Ries CH; Kiessling F; Pöschinger T
PLoS One; 2019; 14(7):e0219517. PubMed ID: 31291357
[TBL] [Abstract][Full Text] [Related]
18. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
[TBL] [Abstract][Full Text] [Related]
19. Bromo- and extraterminal domain protein inhibition improves immunotherapy efficacy in hepatocellular carcinoma.
Liu C; Miao X; Wang Y; Wen L; Cheng X; Kong D; Zhao P; Song D; Wang X; Ding X; Xia H; Wang W; Sun Q; Gong W
Cancer Sci; 2020 Oct; 111(10):3503-3515. PubMed ID: 32726482
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms and network pharmacological analysis of Yangyin Fuzheng Jiedu prescription in the treatment of hepatocellular carcinoma.
Xie Y; Yan F; Wang X; Yu L; Yan H; Pu Q; Li W; Yang Z
Cancer Med; 2023 Feb; 12(3):3237-3259. PubMed ID: 36043445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
